Clinical Trials Logo

Lipid Metabolism, Inborn Errors clinical trials

View clinical trials related to Lipid Metabolism, Inborn Errors.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02830763 Terminated - Clinical trials for Primary Triglyceride Deposit Cardiomyovasculopathy (TGCV)

Clinical Study on the Safety of CNT-02 for TGCV and NLSD-M

Start date: September 5, 2016
Phase: N/A
Study type: Interventional

This study is planning to evaluate the safety and clinical efficacy of medium-chain fatty acid capsules (food-grade CNT-02) in subjects with primary triglyceride deposit cardiomyovasculopathy (TGCV) and neutral lipid storage disease with myopathy (NLSD-M) associated with adipose triglyceride lipase (ATGL) genetic defects.

NCT ID: NCT02104336 Terminated - Pearson Syndrome Clinical Trials

Phase 2 Study of EPI-743 in Children With Pearson Syndrome

Start date: August 31, 2014
Phase: Phase 2
Study type: Interventional

Treatment of Pediatric Subjects with Pearson syndrome

NCT ID: NCT00840112 Terminated - Clinical trials for Peripheral Neuropathy

Vitamin E Treatment for Long-Chain 3-Hydroxyacyl Coenzyme A (CoA) Dehydrogenase (LCHAD) Associated Neuropathy

Start date: July 2010
Phase: N/A
Study type: Interventional

Purpose: People with a genetic defect in the ability to burn fat can also develop a problem with the nerves in their feet. The nerve problem, or neuropathy, can limit their ability to walk. Part of the treatment of their genetic defect in the ability to burn fat is to eat a very low fat diet. Vitamin E is found only in fatty foods like oils and nuts. People with a genetic defect in the ability to burn fat may have low vitamin E because of their low fat diet. The purpose of this study is to test whether vitamin E supplements can improve the nerve function in the feet of people with a genetic defect in the ability to burn fat. Procedures: Blood samples will be drawn at the beginning of the study, after 2 months and after 6 months of vitamin E supplements. The blood will be analyzed for plasma vitamin E concentrations. Around the time of each blood draw subjects will record all the food and beverages he or she consumes for three days. The subject will send the record to the investigator. Subjects will have a physical exam by a doctor specializing in nerves, a neurologist before and after taking vitamin E. They will have nerve function measured with a test called a nerve conduction velocity or NCV. Subjects will be given 800 international units (IU) of vitamin E per day for 6 months.

NCT ID: NCT00260299 Terminated - Clinical trials for Immune System Diseases

Dietary Cholesterol and Defects in Cholesterol Synthesis in Mevalonate Kinase Deficiency

Start date: February 2005
Phase:
Study type: Observational

Participants wanted for study of mevalonate kinase deficiency (MKD), mevalonic aciduria, or hyperimmunoglobulinemia with periodic fever syndrome (HIDS). Patients with MKD (mevalonic aciduria or hyperimmunoglobulinemia with periodic fever syndrome (HIDS)) may be eligible for a research study conducted at Oregon Health & Science University (OHSU) in Portland, Oregon USA. The purpose of the study is to find out more about how these diseases affect body chemistry and health. The researchers also want to find out how cholesterol in the diet affect blood cholesterol and how the body handles cholesterol. This is a short-term and long-term dietary study. The long-term goal of this research is to see if controlling dietary cholesterol can decrease any of the symptoms of the diseases. The study could involve up to 12 one-week admissions to OHSU over the course of 5 years.

NCT ID: NCT00092833 Terminated - Clinical trials for Hypercholesterolemia, Familial

Investigational Drug in Patients With Hypercholesterolemia or in Patients With Sitosterolemia (0653-026)(COMPLETED)

Start date: July 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study is to provide an investigational drug to patients with a specific type of hypercholesterolemia (high cholesterol) or sitosterolemia (unusually high absorption of non-cholesterol sterols) in a treatment use setting.